PDCD1 and melanoma: We and others have previously analyzed ICI use patterns for patients with advanced melanoma primarily in the ipilimumab era, when anti–PD-1 use was likely restricted to clinical trial or off-label use.2,12,29,30,31 Herein we found that first-line ICI use has increased to 63% of newly diagnosed patients with stage IV melanoma in 2019, from 9% in 2010 and 39% in 2015 (the year leading up to FDA approval of first-line anti–PD-1).